Home   >  

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products

Antibodies

Peptides

Catalysts

Impurities

Intermediate

Raw Materials

Angiogenesis/Protein Tyrosine Kinase

Chemical Structure Cat. No. Product Name CAS No.
HIF2α-IN-2 Chemical Structure
BCP37538 HIF2α-IN-2 1672666-82-8
HIF-2α-IN-2 is a hypoxia-inducible factor (HIF-2α) inhibitor (IC50: 16 nM in scintillation proximity assay).
BDTX-189 Chemical Structure
BCP37532 BDTX-189 2414572-47-5
BDTX-189 is a potent, orally active and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations, includes EGFR/HER2 exon 20 insertion mutants. BDTX-189 shows KDs of 0.2, 0.76, 13 and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively. Anticancer activity.
Insulin Chemical Structure
BCP37517 Insulin 12584-58-6
CH7233163 Chemical Structure
BCP37295 CH7233163 CH7233163
CH7233163 overcomes osimertinib resistant EGFR-Del19/T790M/C797S mutation
TL13-12 Chemical Structure
BCP36914 TL13-12 2229037-04-9
TL13-12 is a novel selective anaplastic lymphoma kinase (ALK) degrader.
Remibrutinib Chemical Structure
BCP36887 Remibrutinib 1787294-07-8
Remibrutinib, also known as LOU064, is a Bruton's tyrosine kinase inhibitor.
TL13-112 Chemical Structure
BCP36884 TL13-112 2229037-19-6
TL13-112 shows chemically induced degradation of anaplastic lymphoma kinase (ALK).
Deuruxolitinib Chemical Structure
BCP36774 Deuruxolitinib 1513883-39-0
TAS0728 Chemical Structure
BCP33300 TAS0728 2088323-16-2
TAS0728 is a potent, selective, orally active, irreversible and covalent-binding HER2 inhibitor, binds to HER2 at C805, inhibits its kinase activity, with an IC50 of 13 nM. TAS0728 shows IC50s of 4.9, 8.5, 31, 65, 33, 25, 86 and 36 nM for BMX, HER4, BLK, EGFR, JAK3, SLK, LOK and human HER2, respectively. TAS0728 also inhibits the phosphorylation of HER2, HER3, and downstream effectors, shows no obvious effect on EGFR. Antitumor activity.
Pemigatinib Chemical Structure
BCP31812 Pemigatinib 1513857-77-6
Pemigatinib is an orally active, selective FGFR inhibitor with IC50s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma.
123下一頁末頁共 753 條記錄 1 / 76 頁 
0086-13720134139
福建36选7奖金 最好的免费股票软件 北京一分赛车开奖结果 北京时时彩赛车 一 Welcome 河北20选5中奖注数 江西多乐彩今日开奖结果查询 欢乐联网炸金花_进入游戏 棋牌软件 30选5中奖奖金 排列5开奖情况 北京赛车pk开奖直播手机板 重庆快乐十分彩走势图 广东时时彩开奖结果查询结果一点击进入 安徽25选5开奖查询 重庆快乐10分苹果版本 开元棋牌只输不赢 体彩七星彩开奖号码